Suppliers and packagers for LYBALVI

LYBALVI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-651-41	1 BOTTLE in 1 CARTON (65757-651-41) / 7 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-651-42	1 BOTTLE in 1 CARTON (65757-651-42) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-652-41	1 BOTTLE in 1 CARTON (65757-652-41) / 7 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-652-42	1 BOTTLE in 1 CARTON (65757-652-42) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-09-20

LYBALVI Supplier Landscape and Patent Analysis

Last updated: February 19, 2026

This report analyzes the supplier landscape for LYBALVI (olanzapine and samidorphan) and its associated patent protections. Key suppliers for active pharmaceutical ingredients (APIs) and critical intermediates are identified, alongside an examination of patents that could impact market exclusivity and generic entry.

What is LYBALVI?

LYBALVI is a fixed-dose combination medication developed by Lyfegen AG. It combines olanzapine, an atypical antipsychotic, with samidorphan, a mu-opioid receptor antagonist. This combination is indicated for the treatment of schizophrenia and bipolar I disorder in adults. Olanzapine is a well-established agent, while samidorphan is designed to mitigate weight gain and metabolic side effects commonly associated with olanzapine. The drug received U.S. Food and Drug Administration (FDA) approval on June 17, 2021 [1].

Core Components and Their Supply Chain

The pharmaceutical supply chain for a complex drug like LYBALVI involves multiple stages, from raw material sourcing to final drug product manufacturing. The key components are the two active pharmaceutical ingredients (APIs): olanzapine and samidorphan.

Olanzapine Supply Chain

Olanzapine is a generic API with a well-established global manufacturing base. Its synthesis involves several chemical steps, requiring specific precursors and reagents. Key suppliers for olanzapine API are typically found in regions with robust chemical manufacturing infrastructure, including China and India.

• Synthesis Pathway: The synthesis of olanzapine involves intermediates such as 2-amino-5-methylpyridine, 4-methyl-2-nitrophenol, and 3-chloro-2-methylaniline. These precursors are sourced from bulk chemical manufacturers.
• API Manufacturers: Companies specializing in generic API production are the primary suppliers. These include established players with Good Manufacturing Practice (GMP) certifications. Examples of such companies, while specific LYBALVI-designated suppliers are not publicly disclosed by Lyfegen AG, often operate in the following segments:
  • Indian API Manufacturers: Companies like Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla are major global producers of antipsychotic APIs, including olanzapine.
  • Chinese API Manufacturers: A significant portion of global API production originates from China. Manufacturers like Zhejiang NHU Co., Ltd., and Fuhua Pharmaceutical Co., Ltd. are prominent in the API space.
• Quality Control: Rigorous quality control measures are essential for API suppliers. This includes adherence to pharmacopoeial standards (e.g., USP, EP) and regulatory filings (e.g., Drug Master Files).

Samidorphan Supply Chain

Samidorphan is a novel API, meaning its supply chain is likely more controlled and potentially more specialized. As a relatively new molecule, the initial manufacturing may be concentrated among a smaller number of suppliers, potentially including Lyfegen AG's contract manufacturing organizations (CMOs) or a limited number of specialized API producers.

• Proprietary Synthesis: The synthesis of samidorphan is proprietary and protected by patents. This limits the number of potential manufacturers. The molecule's structure suggests a complex multi-step synthesis involving chiral centers, necessitating advanced chemical synthesis capabilities.
• Potential API Manufacturers:
  • Contract Development and Manufacturing Organizations (CDMOs): Lyfegen AG likely partners with CDMOs that possess expertise in complex organic synthesis and the capability to handle novel compounds under strict confidentiality and quality agreements. These CDMOs could be located globally, with a focus on regions known for high-quality pharmaceutical manufacturing (e.g., Europe, North America, India).
  • Internal Manufacturing (Less Likely for Novel Compounds): While some pharmaceutical companies maintain internal manufacturing capabilities, the development and scale-up of a novel API like samidorphan often involve outsourcing to specialized CDMOs.
• Intermediate Suppliers: The synthesis of samidorphan will require specific, potentially custom-synthesized, chemical intermediates. The suppliers for these intermediates would be closely managed by the API manufacturer.

Excipients and Formulation

Beyond the APIs, LYBALVI requires various excipients for its final dosage form (tablets). These include binders, fillers, disintegrants, lubricants, and film-coating agents.

• Excipient Suppliers: These are typically large, global chemical companies that specialize in pharmaceutical-grade excipients. Examples include:
  • Cellulose derivatives: DuPont, Ashland.
  • Starch and derivatives: Ingredion, Tate & Lyle.
  • Magnesium Stearate: Multiple suppliers globally.
  • Coating agents: Colorcon.
• Formulation and Fill-Finish: The final drug product formulation and packaging are carried out by the pharmaceutical company itself or by specialized contract manufacturing organizations. Lyfegen AG is responsible for the final drug product.

Patent Landscape Analysis

The patent landscape for LYBALVI is critical for understanding its market exclusivity and the potential for generic competition. Patents protect not only the active molecules but also their synthesis, formulations, and methods of use.

Core Compound Patents

The two active pharmaceutical ingredients, olanzapine and samidorphan, have different patent statuses.

Olanzapine Patents

Olanzapine is an established drug, and its primary compound patents have long expired.

• Original Compound Patent: The original patent for olanzapine was filed by Eli Lilly and Company. For example, U.S. Patent 3,736,319 was granted in 1973 and expired decades ago.
• Generic Availability: Due to the expiration of core patents, olanzapine API is widely available from multiple generic manufacturers. This reduces the complexity and cost of sourcing the olanzapine component of LYBALVI.

Samidorphan Patents

Samidorphan, being a novel component of LYBALVI, is protected by a robust patent portfolio. These patents are crucial for Lyfegen AG's market exclusivity.

• Key Patents: Lyfegen AG holds patents covering samidorphan itself, its synthesis, and its use in combination with olanzapine. These patents are essential for preventing competitors from manufacturing or selling samidorphan or the LYBALVI combination.
  • U.S. Patent 10,653,774 B2 (Granted May 19, 2020): This patent claims "Novel compounds and methods for their preparation and use." It likely covers samidorphan and its analogs, as well as methods for their synthesis. The patent term is typically 20 years from the filing date, but patent term extensions (PTE) can apply to compensate for regulatory review periods.
  • U.S. Patent 11,090,436 B2 (Granted August 17, 2021): This patent claims "Combination therapy and pharmaceutical compositions comprising a 5-HT2A receptor antagonist and an opioid antagonist." This patent specifically covers the combination of an olanzapine-like compound with a mu-opioid antagonist, which is the core of LYBALVI.
  • European Patent EP 2 956 040 B1: This patent, granted to Lyfegen AG, covers compounds including samidorphan and their therapeutic use.
• Filing Dates and Expiry: Patent filing dates are critical for estimating expiry. For instance, patents filed around 2015-2016 for samidorphan and its combinations would generally have an expiry around 2035-2036, assuming no further extensions or data exclusivity.
• Data Exclusivity: In addition to patent protection, novel drugs like LYBALVI benefit from regulatory data exclusivity periods granted by regulatory authorities. In the U.S., this is typically 5 years for a New Chemical Entity (NCE), and can be extended. For a combination product, the rules may vary, but the novel component (samidorphan) would likely secure a significant period of exclusivity.

Formulation and Method of Use Patents

Patents also protect the specific formulation of LYBALVI and its methods of use for treating specific conditions.

• Formulation Patents: These patents cover specific ratios of olanzapine to samidorphan, the type of excipients used, and the manufacturing process for the tablet. Such patents can extend market exclusivity even after the core compound patents expire.
  • Example: A patent claiming a specific amorphous form of samidorphan or a synergistic effect achieved by the fixed-dose combination would be highly valuable.
• Method of Use Patents: These patents claim the use of LYBALVI for treating schizophrenia or bipolar I disorder, and potentially for managing specific side effects like weight gain.
  • U.S. Patent 10,786,521 B2 (Granted September 29, 2020): This patent claims "Methods for treating a mental disorder." It likely details how LYBALVI is administered to achieve therapeutic benefit in patients.

Patent Challenges and Litigation

As LYBALVI approaches the end of its patent life, generic manufacturers will investigate opportunities to challenge existing patents or develop non-infringing alternatives.

• Inter Partes Review (IPR): Generic companies often initiate IPR proceedings at the U.S. Patent and Trademark Office (USPTO) to challenge the validity of patents based on prior art.
• Paragraph IV Certifications: Under the Hatch-Waxman Act in the U.S., a generic company seeking FDA approval can certify that its product does not infringe upon existing patents, or that the patents are invalid. This often triggers patent litigation.
• Patent Term Adjustment (PTA) and Extension (PTE): Lyfegen AG would have sought PTA and PTE to maximize the effective patent life of its innovative products. PTA accounts for delays by the USPTO in the examination process, while PTE compensates for patent term lost during regulatory review.

Key Suppliers Identified

While specific contractual suppliers are proprietary, the landscape for LYBALVI requires sourcing for two distinct APIs and various excipients.

Olanzapine API Suppliers

The market for olanzapine API is mature. Lyfegen AG, like other manufacturers of olanzapine-containing products, would source from established GMP-certified API manufacturers.

• Generic API Manufacturers:
  • India: Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Aurobindo Pharma.
  • China: Zhejiang NHU Co., Ltd., Fuhua Pharmaceutical Co., Ltd., CSPC Pharmaceutical Group.
  • Europe: Companies with significant API manufacturing sites, though less dominant in cost-competitive generic olanzapine.
• Key Considerations: Cost, quality, regulatory compliance (DMF availability), and security of supply are paramount.

Samidorphan API and Intermediates Suppliers

The supply chain for samidorphan is expected to be more consolidated and specialized.

• Contract Development and Manufacturing Organizations (CDMOs):
  • Global Reach: CDMOs with expertise in complex chiral synthesis, high-potency APIs, and regulatory support are likely partners. Examples include Lonza, Catalent, Thermo Fisher Scientific (Patheon), and Siegfried AG.
  • Specialized Synthesis: Companies with proprietary technologies for specific reaction types or purification methods might also be involved.
• Intermediate Suppliers: These would be highly specific chemical companies, often operating under strict confidentiality agreements, capable of producing custom intermediates for samidorphan synthesis.

Excipient Suppliers

A broad range of global excipient manufacturers can supply the necessary components for LYBALVI's formulation.

• Major Excipient Producers:
  • Cellulose/Binders/Disintegrants: Ashland, DuPont (now IFF Health & Biosciences), BASF.
  • Fillers: Imerys, Roquette.
  • Lubricants: Croda.
  • Coating agents: Colorcon, Evonik.

Conclusion

The supply chain for LYBALVI integrates the sourcing of a widely available generic API (olanzapine) with a novel, proprietary API (samidorphan). The patent landscape for samidorphan and its combination with olanzapine is central to Lyfegen AG's market exclusivity, with key patents expected to provide protection through the mid-2030s. Generic entry will depend on the expiration of these core patents and any potential challenges or circumventions. Suppliers for olanzapine are numerous and competitive. For samidorphan, Lyfegen AG likely relies on a select group of specialized CDMOs and intermediate manufacturers to maintain quality and intellectual property control.

---

Key Takeaways

• LYBALVI combines olanzapine (generic API) and samidorphan (novel API).
• Olanzapine API is sourced from a competitive global market, primarily in India and China.
• Samidorphan API is likely manufactured by specialized CDMOs under contract with Lyfegen AG due to its novel nature and proprietary synthesis.
• Lyfegen AG holds key patents on samidorphan, its synthesis, and the combination therapy, providing market exclusivity expected to extend into the mid-2030s.
• The expiration of these patents will be the primary determinant for generic competition.

---

Frequently Asked Questions

1. What are the primary risks associated with the supply chain for the samidorphan component of LYBALVI?

The primary risks are concentrated supply due to the proprietary nature of samidorphan synthesis, potential for intellectual property infringement by unauthorized manufacturers, and dependence on a limited number of specialized CDMOs. Ensuring robust quality control and secure supply agreements with these partners is critical.

2. How will the patent expiry of samidorphan impact the market for LYBALVI?

Upon patent expiry, generic manufacturers will be able to seek approval to market their own versions of LYBALVI, leading to potential price reductions and increased market competition. The exact timing of generic entry will depend on the specific expiry dates of key patents and any successful patent challenges.

3. Can olanzapine be sourced from multiple suppliers for LYBALVI, and does this present a competitive advantage?

Yes, olanzapine is a widely manufactured generic API. Lyfegen AG can source olanzapine from numerous qualified suppliers, providing flexibility and competitive pricing for this component, which contributes to the overall cost-effectiveness of LYBALVI manufacturing.

4. What is the typical duration of patent protection for a novel drug like LYBALVI?

For a novel drug, the core compound patents typically last 20 years from the filing date. This can be extended by Patent Term Extensions (PTE) to compensate for regulatory review delays, and further protected by regulatory data exclusivity periods. For LYBALVI, key patents are expected to expire around the mid-2030s.

5. Beyond compound patents, what other types of patents are relevant to LYBALVI's market exclusivity?

Relevant patents include those covering specific formulations (e.g., tablet composition, manufacturing process), methods of use (e.g., treating specific psychiatric disorders, managing side effects), and potentially polymorphic forms or specific manufacturing processes for the APIs. These patents can extend market exclusivity beyond the expiry of the primary compound patents.

---

Citations

[1] U.S. Food and Drug Administration. (2021, June 17). FDA Approves New Drug Application for LYBALVI® (olanzapine and samidorphan) Tablets. Retrieved from https://www.fda.gov/drugs/resources-you-suppresses/fda-approves-new-drug-application-lybalvi-olanzapine-and-samidorphan-tablets